Cargando…
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
BACKGROUND: Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders’ preferences and be explicit about the trade-offs that are being...
Autores principales: | Garau, Martina, Hampson, Grace, Devlin, Nancy, Mazzanti, Nicola Amedeo, Profico, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972119/ https://www.ncbi.nlm.nih.gov/pubmed/29623625 http://dx.doi.org/10.1007/s41669-017-0048-x |
Ejemplares similares
-
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study
por: Townsend, William, et al.
Publicado: (2023) -
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL
por: Graf, Solomon A., et al.
Publicado: (2022) -
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)
por: de Andrés-Nogales, Fernando, et al.
Publicado: (2021) -
Development and pilot of a multicriteria decision analysis (MCDA) tool for health services administrators
por: Blythe, Robin, et al.
Publicado: (2019) -
A multicriteria decision analysis (MCDA) tool to purchase implantable medical devices in Egypt
por: Elezbawy, Baher, et al.
Publicado: (2022)